论文部分内容阅读
目的探讨树突状细胞-细胞因子激活的杀伤细胞免疫疗法(DC-CIK)与化疗联合治疗消化道肿瘤的临床疗效与安全性。方法选取2013年1月至2015年1月间大连市中心医院收治的116例晚期消化道肿瘤患者,采用随机数字表法分为研究组与对照组,每组58例。研究组患者在对照组化疗疗法基础上采用DC-CIK治疗,对照组患者单纯采用奥沙利铂、氟尿嘧啶和甲酰四氢叶酸(FOLFOX方案)化疗治疗。结果研究组患者有效率为60.3%,高于对照组的41.4%,两组比较,差异有统计学意义(P<0.05)。研究组患者免疫功能指标CD+4与CD+3均高于对照组,CD+8低于对照组,两组比较,差异均有统计学意义(均P<0.05)。两组患者药物不良反应比较,差异无统计学意义(P>0.05)。随访1年,研究组患者无进展生存率为25.9%和总生存率为34.5%,高于对照组的17.2%和25.9%,差异均有统计学意义(均P<0.05)。结论 DC-CIK与化疗联合治疗消化道肿瘤,可有效提高患者免疫功能,强化化疗敏感性,保证治疗效果,延长生存周期,适于临床推广。
Objective To investigate the clinical efficacy and safety of dendritic cell-cytokine-activated killer cell immunotherapy (DC-CIK) combined with chemotherapy in the treatment of gastrointestinal tumors. Methods A total of 116 patients with advanced gastrointestinal cancer admitted to Dalian Central Hospital from January 2013 to January 2015 were randomly divided into study group and control group with 58 cases in each group. Patients in the study group were treated with DC-CIK on the basis of chemotherapy in the control group, while those in the control group were treated with oxaliplatin alone, fluorouracil and leucovorin (FOLFOX regimen). Results The effective rate of study group was 60.3%, which was higher than that of control group (41.4%). There was significant difference between the two groups (P <0.05). The immune function indexes CD + 4 and CD + 3 of study group were higher than that of control group, but CD + 8 was lower than that of control group. The differences between the two groups were statistically significant (all P <0.05). Two groups of patients with adverse drug reactions, the difference was not statistically significant (P> 0.05). The follow-up of 1 year, the study group patients with progression-free survival rate was 25.9% and overall survival rate was 34.5%, 17.2% and 25.9% higher than the control group, the difference was statistically significant (P <0.05). Conclusion DC-CIK combined with chemotherapy in the treatment of gastrointestinal tumors can effectively improve immune function, enhance chemosensitivity, to ensure the treatment effect, prolong the life cycle, suitable for clinical promotion.